FDA Clears Tubeless Insulin Pump Supplies for Tandem Mobi

The clearance adds tubeless wear to the existing Mobi pump, with tubeless supplies expected to launch in 2027 through the pharmacy benefit.

Updated on Nov. 16, 2026 in Diabetes

Isometric editorial illustration of a cylindrical reservoir connected by coiled tubing to a flat adhesive disc, in deep teal, cream, and mustard.
The FDA cleared a tubeless cartridge and infusion set for Tandem's Mobi insulin pump on November 12, 2026, adding a third U.S. tubeless automated insulin delivery system. AI Illustration. Upload story photo >

Live Poll

Do you trust insurers to choose the best diabetes devices for patients?

The FDA cleared a tubeless cartridge and infusion set for Tandem's Mobi insulin pump on November 12, 2026. The new supplies convert the existing pump, letting users switch between tubed and tubeless wear on the same device.

Why it matters

The clearance adds a third U.S. tubeless automated insulin delivery system, giving people with diabetes another option for wearing insulin delivery equipment. Coverage changes on January 1, 2027, will also shift which glucose sensors major pharmacy-benefit plans favor.

The clearance covers up to 7 days of wear for the infusion set and 3 days for the cartridge, and Control-IQ+ lowered HbA1c by 0.9 percentage points in insulin-treated type 2 diabetes versus 0.3 points with CGM alone in the 2IQP trial. Whether these trial results translate to tubeless users specifically has not been reported.

The players

Tandem Diabetes Care

Tandem Diabetes Care is a San Diego-based maker of insulin pumps, including the Mobi and t:slim X2 systems, known for its Control-IQ automated insulin delivery algorithm.

CVS Caremark

CVS Caremark is the pharmacy benefit manager of CVS Health and one of the largest administrators of prescription drug coverage in the United States.

Aetna

Aetna is a major U.S. health insurer owned by CVS Health that offers commercial and Medicare coverage across the country.

Senseonics

Senseonics Holdings is a medical device company developing the Freedom implantable continuous glucose monitoring system.

The details

The new supplies attach to the existing Mobi pump so users can wear it tubeless on the arm or switch to tubing at a less visible site. Mobi still requires daily charging and pairs only with Dexcom CGMs.

Timeline

  1. November 12, 2026: FDA clears tubeless cartridge and infusion set for Mobi.

  2. January 1, 2027: CVS Caremark and Aetna formularies switch to exclusive FreeStyle Libre coverage.

  3. 2027: Tandem expects tubeless supplies to launch; Senseonics plans a pivotal trial of Freedom.

  4. 2028: Potential launch of Senseonics' Freedom implantable CGM.

Big Picture

The clearance extends Tandem's Control-IQ automated insulin delivery algorithm, now cleared for type 1 diabetes patients aged 2 years and older, onto a tubeless device. It positions the Mobi against other tubeless automated systems already on the U.S. market.

Users who want to avoid visible tubing can wear the Mobi tubeless on the arm, or switch to tubing at a less visible site on the same pump. Tubeless supplies will be available only through the pharmacy benefit, so coverage will shape out-of-pocket costs.

The takeaway

Patients weighing insulin pump options should check which glucose sensors and supply channels their pharmacy benefit covers before the January 2027 formulary change. Tubeless wear can be a practical choice for those who want the device out of sight.

What happens next

Tandem expects its tubeless supplies to launch in 2027, and CVS Caremark and Aetna switch to exclusive FreeStyle Libre coverage on January 1, 2027.

Further reading

For related coverage of treatment devices and advances, see our Diabetes section.

Live Poll

Do you trust insurers to choose the best diabetes devices for patients?